Clinical trials: Tamoxifen
Breast Neoplasms, mTor Protein
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation anti-aromatase hormonotherapy in adjuvant or in metastatic line.
- Trial name
- NCT01298713
- Testing
- Tamoxifen, Everolimus
- Where
- France
- Volunteers
- 111 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Neoplasms, Invasive Breast Cancer
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer.
- Conditions
- Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- EVANGELINE (NCT05607004)
- Testing
- (Z)-endoxifen, goserelin
- Where
- 14 sites in United States
- Volunteers
- 87 people
- Sponsor
- Atossa Therapeutics, Inc.
Breast Cancer
Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients.
This is a multicenter, prospective, randomized controlled, phase II study. The primary objective is to evaluate the effect of endocrine therapy modification (switching from a 3-month to a 1-month GnRHa) versus continuation of the…
- Trial name
- IFOCOS (NCT07610733)
- Testing
- 1-month GnRH, 3-month GnRH
- Volunteers
- 100 people
- Sponsor
- Fudan University
HR Positive HER2 Negative Advanced Breast Cancer
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
To explore the efficacy and safety of Chidamide combined with endocrine for maintenance therapy after first-line chemotherapy for HR+/HER2- breast cancer
- Trial name
- NCT05890287
- Testing
- Chidamide
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Neoplasms
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer.
- Trial name
- preEMBER (NCT07287098)
- Testing
- Imlunestrant, Goserelin, Tamoxifen 20 mg
- Where
- 87 sites in United States, Belgium and 5 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
ERα+ Breast Cancer, ESR1 Gene Mutation
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
Despite broad advancements in endocrine therapy for ERα+ breast cancer, resistance ultimately develops. A common driver of resistance are known ESR1 mutations that lead to constitutively active receptor signaling and…
- Trial name
- NCT04174352
- Testing
- Tamoxifen, FES PET/CT
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
Hormone receptor-positive breast cancer accounts for about 70% of all breast cancers. Extended endocrine therapy with aromatase inhibitor is the current main treatment for hormone receptor-positive breast cancer.
- Trial name
- NCT04476485
- Testing
- endocrine therapy
- Where
- 12 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Shengjing Hospital
Breast Cancer
Tamoxifen in Treating Women With High-Risk Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002542
- Testing
- CMF regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in Canada
- Volunteers
- 672 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response…
- Trial name
- PHERGain (NCT03161353)
- Testing
- Perjeta, Herceptin, Docetaxel
- Where
- 56 sites in Belgium, France and 5 more
- Volunteers
- 377 people
- Sponsor
- MedSIR
Hereditary Hemorrhagic Telangiectasia
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
Hereditary hemorrhagic telangiectasia (HHT) is associated with recurrent epistaxis in 90% of cases. Good response to hormone treatment has been documented, although its use remains controversial.
- Trial name
- NCT00375622
- Testing
- Tamoxifen
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Rabin Medical Center
Breast Cancer
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen
Aim of work: 1. To estimate the frequency of Cyp2D6*1 and *4 alleles in Egyptian patients maintained on tamoxifen (20 mg/day) for management of ER +ve breast cancer. 2.
- Trial name
- NCT03582865
- Testing
- Tamoxifen 20 mg
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Cancer, Menopausal Symptoms
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about differences in DNA and predict how well patients will respond to treatment and plan better treatment.
- Trial name
- NRR (NCT00764322)
- Testing
- tamoxifen citrate, gene expression analysis, pharmacogenomic studies
- Where
- 7 sites in United States
- Volunteers
- 501 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Schizophrenia, Schizoaffective Disorder
Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in the treatment of young women with schizophrenia and schizoaffective disorder.
- Trial name
- NCT02354001
- Testing
- Raloxifene hydrochloride
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- The Alfred
Mastalgia
External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe Mastalgia
This is a single-center, double-blind, double-simulated, positive-controlled, randomized clinical trial to explore the efficacy and safety of external mastalgia-oil versus oral tamoxifen in premenopausal women with severe…
- Trial name
- NCT06404775
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Postmenopause
AFTER: Altering Fat Through Estrogen and Raloxifene
The purpose of this study is to determine whether estrogens specifically promote a reduction in fat from abdominal regions during weight loss and/or prevent the accumulation of abdominal fat during weight gain.
- Trial name
- NCT00149604
- Testing
- conjugated estrogens, Raloxifene, exercise plus mild caloric restriction for weight loss
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Breast Cancer
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic or…
- Trial name
- TH3RESA (NCT01419197)
- Testing
- Trastuzumab emtansine, Treatment of physician's choice
- Where
- 184 sites in United States, Australia and 20 more
- Volunteers
- 602 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel followed by surgery in…
- Trial name
- NCT00003953
- Testing
- filgrastim, CMF regimen, docetaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Case Comprehensive Cancer Center
Ovarian Cancer
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer.
- Trial name
- TICTOC (NCT05156892)
- Testing
- SUBA-itraconazole, Tamoxifen
- Where
- Australia
- Volunteers
- 44 people
- Sponsor
- Anthony Joshua, FRACP
Breast Neoplasm Malignant Primary, Lymphedema Arm
Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors
As survival rates following breast cancer surgery continue to improve, long-term survivorship management has emerged as a crucial clinical priority.
- Conditions
- Breast Neoplasm Malignant Primary, Lymphedema Arm, Medication Adherence, Ductal Carcinoma In Situ
- Trial name
- Pinkmate (NCT07911839)
- Testing
- Cohort1: Pinkmate Agentic AI-ePRO Active Management Platform, Cohort1: Pinkmate Basic Medication Reminders and Standard Outpatient Care, Cohort2: InBody BWA ON Home Bioimpedance Monitoring and Behavioral App
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Chang-Ik Yoon